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Abstract.  Most patients with the autosomal recessive 
disease primary hyperoxaluria type 1 (PHI) have a 
complete deficiency of alanine/glyoxylate aminotrans- 
ferase (AGT) enzyme activity and immunoreactive 
protein.  However a few possess significant residual ac- 
tivity and protein.  In normal human liver, AGT is en- 
tirely peroxisomal,  whereas it is entirely mitochondrial 
in carnivores,  and both peroxisomal and mitochondrial 
in rodents.  Using the techniques of isopycnic sucrose 
and Percoll density gradient centrifugation and quan- 
titative protein A-gold immunoelectron microscopy, we 
have found that in two PHI patients,  possessing 9 and 
27%  residual AGT activity, both the enzyme activity 
and immunoreactive protein were largely mitochon- 
drial and not peroxisomal.  In addition,  these individu- 
als were more severely affected than expected from the 
levels of their residual AGT activity. In these patients, 
the PHI appears to be due, at least in part,  to a 
unique trafficking defect, in which peroxisomal AGT 
is diverted to the mitochondria.  To our knowledge, 
this is the first example of a genetic disease caused by 
such interorganellar  rerouting. 
p 
RIMARY hyperoxaluria  type 1 (PH1)  j is an autosomal 
recessive disease caused by a deficiency of the hepatic 
peroxisomal enzyme alanine/glyoxylate  aminotrans- 
ferase (AGT) (Danpure  and Jennings,  1986). Most PH1 pa- 
tients  have a complete deficiency of AGT enzyme activity 
(Danpure  and Jennings,  1988)  and  AGT immunoreactive 
protein  (Wise  et al.,  1987).  However a  minority  possess 
significant  quantities  of residual  enzyme activity and pro- 
tein.  In these cases, there appears  to be a relationship  be- 
tween the amount of residual AGT activity and various mark- 
ers of disease severity (Danpure et al.,  1987). 
Unlike the rat,  where hepatic AGT is partly peroxisomal 
and partly mitochondrial  (Noguchi et al., 1979), and the cat, 
where it is entirely mitochondrial  (Okuno et al.,  1979), hu- 
man hepatic  AGT is entirely  peroxisomal, both in normals 
(Noguchi and Takada,  1979; Yokota et al.,  1987; Cooper et 
al.,  1988a,b)  and in those PH1 patients,  studied so far, who 
possess AGT  protein  (Wise  et  al.,  1987; Cooper et  al., 
1988a,b). 
In the present study, we have investigated the intracellular 
distribution  of AGT enzyme activity  and  immunoreactive 
protein  in  two  PH1  patients  who  possessed  significant 
amounts  of residual  AGT activity. It appears that these pa- 
1. Abbreviations used in this paper: AGT, alanine/glyoxylate aminotransfer- 
ase; PHI, primary hyperoxaluria type 1; SPT, serine/pyruvate aminotrans- 
ferase. 
tients are examples of a unique type of trafficking defect in 
which peroxisomal  AGT is rerouted to the mitochondria. 
Materials and Methods 
Patients~Livers 
Patient  1 was a  16-yr-old male with pyridoxine-resistant PH1.  He had 
hyperoxaluria and hyperglycolic aciduria, a history of calcium oxalate kid- 
ney stones, and had reached end-stage renal failure requiring him to be on 
haemodialysis.  Complete hepatectomy was performed before combined 
liver and kidney transplantation (see Watts et al., 1987).  Patient 2 was a 33- 
yr-old male with pyridoxine-responsive PH1.  He had a history of calcium 
oxalate kidney stones, and when withdrawn from pyridoxine had marked 
hyperoxaluria and hyperglycolic aciduria. A liver sample was obtained for 
verification of the diagnosis by percutaneous needle biopsy. Diagnostic per- 
cutaneous needle biopsies were also taken from controls 1 and 2 for sus- 
pected liver disease. Control 1 was a male patient suffering from Gilbert's 
syndrome. The liver was histologically normal.  Control 2  was a  female 
schizophrenic patient  suffering  from  chlorpromazine toxicity.  She  had 
peroxisomal and mitocbondrial proliferation and had been shown previ- 
ously to have elevated levels of hepatic AGT. These two controls were cho- 
sen because preliminary immunocytochemical experiments had shown that 
their levels of immunoreactive AGT protein covered the extremes of the nor- 
mal range (control 1 was the lowest and control 2 was the highest). Control 
3 was an asymptomatic obligate PHI heterozygote. Her hepatic AGT activ- 
ity was about one-third of the normal level (Danpure and Jennings, 1988). 
An open liver biopsy was obtained from this individual while under general 
anaesthesia. Where appropriate, informed consent was given. These studies 
were approved by the Ethical Committee of the Harrow Area Health Au- 
thority. 
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liver were sonieated in 0.1  tool/liter potassium phosphate buffer,  pH 7.4, 
containing 0.1  mmol/liter pyridoxal phosphate, as described previously 
(Danpure et al.,  1987). 
SubceUular Fractionation 
Sucrose Gradients.  The homogenization and isopycnic sucrose gradient 
centrifugation were carried out as described previously (Danpure et al., 
1986).  Briefly,  fresh samples of liver (from patient 1 only) were homog- 
enized in 0.25 mol/liter sucrose, containing 1 mmol/liter EDTA, pH 7.4, 
to give a concentration of 20%  (wt/vol). After centrifuging for 10 min at 
600 g, the supernatant (4 ml) was layered onto a sucrose gradient (30 ml, 
1.05-1.30  g/cm  3)  and  centrifuged at  72,000  g  for 60  min  in  a  vertical 
pocket rotor.  Fractions (2 ml) were collected from the bottom and assayed 
for enzyme activity and immunoreactive AGT protein. 
PercoU Gradients.  An organellar fraction (from patient 1 only) was pre- 
pared by centrifuging a postnuclear supernatant at  105,000 g for 30 min. 
The pellet was gently rehomogenized in 0.25 mol/liter sucrose containing 
1.0 mmol/liter EDTA, pH 7.4. An aliquot (2 ml) was mixed with 27 m150% 
Percoll in 0.25  mol/liter sucrose containing 1 mmol/liter EDI'A, pH 7.4, 
and then layered over 1 ml 2.4 mol/liter sucrose and spun at 83,000 g for 
45 min in a vertical pocket rotor (Neat et al., 1980).  Fractions (2 ml) were 
collected from the bottom and assayed for enzyme activity. 
Enzyme Assays 
Alanine/2-oxoglutarate aminotransferase (EC 2.6.1.2),  glutamate/glyoxytate 
aminotransferase (EC 2.6.1.4),  catalase (EC 1.11.1,6), D-amino acid oxidase 
(EC 1.4.3.3.),  cytochrome oxidase (EC 1.9.3.1), and lactate dehydrogenase 
(EC 1.1.2.3) were assayed as previously described (Danpure and Jennings, 
1988). AGT (EC 2.6.1.44)  in the sucrose and Percoll gradient fractions was 
assayed by the radiochemieal micromethod of Allsop et al. (1987),  while 
that in the liver sonicates was assayed using the spectrophotometric method 
described in Danpure and Jennings (1988).  Protein was measured by the 
method of Lowry et al.  (1951). 
Immunoblotting 
Samples of liver sonicates (50 #g protein) and fractions from the sucrose 
gradients (20 #1) were fractionated on SDS-PAGE and immunoblotted, as 
described previously (Wise et al., 1987), except that the first antibody (rab- 
bit anti-human liverAGT IgG) was affinity  purified by passing down an 
AGT-Sepharose column, absorbing against a human liver sonicate deficient 
in immunoreactive AGT protein, and passing down a protein A-Sepharose 
column. This IgG preparation detected a single 40-kD band in normal liver 
sonicate, identical to that produced by purified AGT. In some individuals 
an extra faint band at 43 kD was also detected. 
lmmunocytochemistry/Morphometry 
Fresh liver samples were fixed in  1%  glutaraldehyde and  embedded in 
Lowicryl K4M (Carlemalm et al.,  1982).  Immunoreactive AGT protein 
was visualized by postembedding immunocytochemistry using the protein 
A-gold technique (Roth,  1982)  as described previously (Cooper et al., 
1988b).  Catalase was visualized in the same manner, except that the anti- 
body was sheep anti-bovine catalase (Serotec, Kidlington, Oxford, UK) 
diluted 1:20 and protein A-gold was replaced by protein G-gold (Bendayan, 
1987).  Morphometric quantitation of the gold labeling was carried out as 
described before Cooper et al. (1988b).  Briefly, this involved calculating the 
mitochondrial and peroxisomal profile areas from randomly selected cyto- 
plasmic fields, using a Reichert MOP Videoplan image analyzer (Kontron 
Instruments, Slough, Bucks, UK). Labeling density was estimated by count- 
ing the number of gold particles over each organelle or area of cytoplasm 
of interest and expressing this as particles per micrometers squared. All mi- 
tochondrial or peroxisomal profiles lacking  gold were counted as zero 
values to obtain a true estimate of the mean labeling density for AGT. Such 
zero values were only observed in patients 1 and 2. In control livers >99% 
of the peroxisomal profiles showed significant label. The number of peroxi- 
somes or mitochondria in a unit area of cytoplasm (i.e., excluding nuclei 
and sinusoidal spaces) was calculated from randomly chosen low-power 
negatives (6,850x).  For each individual liver,  between 1,300  and 2,000 
/zm  2 of cytoplasm was used to estimate the organelle frequency. We were 
able to estimate the "total" (T) mitochondrial or peroxisomal labeling for 
AGT in an average of 100/xm  z of liver cytoplasm for each individual by the 
following equation: 
T=LxAxN, 
where L  =  the mean mitochondrial or peroxisomal gold labeling density 
(particies//~m2);  A  =  the mean mitochondrial or peroxisomal profile area 
(~m2); and  N  =  the  mean  number  of mitochondria  or  peroxisomes 
(profiles/100/~m 2 of cytoplasm). This allows for comparison of the relative 
contributions made by each organelle to the total liver AGT in each patient. 
Results 
Both patients 1 and 2 were more severely affected than would 
be expected from the amounts of residual AGT activity found 
in their livers.  Patient 1, who had 8.7% residual corrected 
AGT activity (Table I), had pyridoxine-resistant PHI of such 
severity that he required a combined liver/kidney transplant. 
His clinical condition was indistinguishable from the ma- 
jority of PHI patients who had no (<2%) residual hepatic 
AGT activity. In comparison, the clinical condition of two 
other patients with similar residual AGT levels (13 and 14%) 
was considerably milder than that of patient 1. 
Patient 2 had a milder form of pyridoxine-responsive PHI. 
His residual level of hepatic AGT (27.1% when corrected) 
was much higher than that in patient 1 (Table I). This level 
was similar to that found previously in asymptomatic ob- 
ligate heterozygotes (Danpure and Jennings,  1988). 
Isopycnic sucrose gradient centrifugation showed that total 
(uncorrected) AGT activity in patient 1 was partly mitochon- 
drial and partly cytosolic (Fig.  1).  Most, if not all, of the 
cytosolic AGT activity could be accounted for by cross-over 
from another enzyme glutamate/glyoxylate  aminotransferase 
(Danpure and Jennings, 1988; Cooper et al., 1988b).  When 
corrected for this cross-over (Fig. 2 A), the distribution of 
AGT activity was entirely mitochondrial. When a  similar 
correction was applied to sucrose gradients from four other 
PHI  livers, any slight indication of mitochondrial activity 
completely disappeared (Fig. 2 B). Immunoblotting of the 
Table L Hepatic AGT Activities 
Enzyme Activity 
AGT  GGT  AGT*  AGT* 
Patient  ! 
Patient 2 
Other PHI  patients 
Mean 
Range 
n 
Control 2 
Control 3 
Other controls 
Mean 
Range 
n 
% of control 
0.98  0.90  0.39  9 
1.97  1.14  1.22  27 
0.63  0.78  0.15  3 
(0.27-1.32) (0.44-1.03) (0.00-0.64) 
20  17  17 
9.86  +  9.43  210 
2.00  0.84  1.45  32 
5.00  0.65  4.50 
(3.25-8.99) (0.38-0.92) (2.75-8.38) 
16  12  12 
100 
Units are in #mol/h per mg protein.  AGT*, AGT activity corrected for 66% 
cross-over from glutamate/glyoxylate  aminotransferase  (GGT).  The rationale 
for this correction and the data for the other PHI patients and controls are taken 
from Danpure  and Jennings  (1988).  The percent values are based on the ap- 
propriate  mean of other normal controls.  +, the biopsy for control 2 was too 
small to measure  GGT.  Therefore the corrected AGT* value  is an estimate 
based on the mean normal control GGT level. Patients  1 and 2, PHI patients; 
control 2,  schizophrenic  patient with chlorpromazine  toxicity;  control 3, ob- 
ligate PHI  heterozygote. 
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Figure 1. Subcellular distribution of total AGT enzyme activity on 
a sucrose gradient (patient 1). A, AGT; B, cytochrome  oxidase (mi- 
tochondria); C, D-amino acid oxidase (peroxisomes); D, gluta- 
mate/glyoxylate aminotransferase (cytosol); E, alanine/2-oxoglu- 
tarate aminotransferase  (cytosol);  F, lactate  dehydrogenase  (cytosol). 
Fraction 1, bottom of gradient. Units of enzyme activity equal per- 
cent of total gradient activity recovered in each fraction. G and H, 
distribution of AGT (e), D-amino  acid oxidase (o), and cytochrome 
oxidase (o) in normal human liver (data taken from Danpure and 
Jennings, 1986) and a PHI heterozygote  liver (control 3) (data taken 
from Danpure and Jermings, 1988). 
sucrose gradient fractions showed that the 40-kD immuno- 
reactive AGT protein was also mitochondrial (Fig. 3).  An 
immunoreactive band  of slightly higher  molecular  mass 
('~43 kD) was also found, but this was restricted to the top 
of the gradient (cytosolic fractions). 
Confirmation of the mitochondrial location of AGT was 
achieved when Percoll was used. On such gradients, it could 
be clearly seen that the vast majority, if not all, of the AGT 
activity (Fig. 4) in patient 1 was associated with the mito- 
chondria rather than the peroxisomes. Even the small amount 
cofractionating with the catalase (peroxisomal marker) peak 
might have been due to mitochondrial damage caused by re- 
suspension of the organellar pellet, as some cytochrome oxi- 
dase, but not glutamate dehydrogenase, was also found in 
this fraction (Fig. 4). 
Quantitative protein A-gold immunocytochemistry con- 
finned the results obtained by isopycnic density gradient cen- 
trifugation, both in this and previous studies (Danpure and 
Jennings,  1986, 1988;  Cooper et al.,  1988a,b).  The three 
control livers possessed a wide range of AGT enzyme activi- 
ties, which was paralleled by an equally wide range in the 
level of immunoreactive AGT protein, as reflected by total 
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Figure 2. Subcellular  distribu- 
tion of "corrected" AGT ac- 
tivity on  a  sucrose gradient 
(patient 1). A, patient 1; B, a 
"typical" PHI patient with no 
AGT enzyme activity (three 
others were almost identical). 
Open histogram denotes total 
AGT activity; solid histogram 
denotes AGT activity  corrected 
for cross-over from glutamate/ 
glyoxylate  aminotransferase 
(Danpure and Jennings, 1988). 
Fraction  1,  bottom of gradi- 
ent. P, M, and C, positions of 
peroxisomal,  mitochondrial, 
and cytosolic  markers, respec- 
tively. Units of AGT activity 
equal #mol/h per mg protein. 
gold labeling (Table II, Fig. 5, a and b). As found previously 
(Cooper et al., 1988a,b), virtually all the gold labeling was 
peroxisomal, while the labeling densities in the mitochon- 
dria were hardly above the background level (Table II, Fig. 
5, a  and b). 
Patient 1 had much lower levels of gold labeling than the 
controls (Table II, Fig. 5 c), which was compatible with his 
low levels of AGT enzyme activity (Table I). Nevertheless 
morphometric analysis confirmed that most of his immu- 
noreactive AGT protein was mitochondrial. The gold label- 
ing density in the peroxisomes was only ~1% of that in the 
controls  (29-168  reduced  to  0.7  particles/t~m2),  whereas 
that in the mitochondria was increased '~10 times (0.15-0.25 
increased to 2.2) (Table II). It could be estimated that the to- 
tal  mitochondrial immunoreactive AGT  protein  was  "~17 
times greater than that contributed by the peroxisomes in pa- 
tient  1 (Table  II).  Most of the increase  in mitochondrial 
labeling was due to an increase in the proportion of mito- 
chondria containing detectable immunoreactive protein (from 
~4 to 42%), as the mean labeling density of  only those mito- 
chondria labeled hardly changed (Table III). 
The size of the liver biopsy from patient 2 was too small 
to  perform  subcellular  fractionation.  However the  much 
higher amounts of immunoreactive AGT protein in this pa- 
tient made quantitative protein A-gold immunocytochemis- 
try more conclusive than with patient 1. Patient 2 had levels 
of AGT enzyme activity (Table I) and immunoreactive AGT 
protein (represented by total gold labeling) (Table II, Fig. 5 
d) similar to those of control 3 (an obligate PH1 heterozy- 
gote). In this patient, the mitochondrial gold labeling density 
was at least 20 times greater than that found in the controls 
(0.15-0.25  increased to 4.7 particles/#m  2) (Fig. 5, Table II), 
whereas the peroxisomal labeling density was reduced '~20- 
fold  (29-168  reduced  to  4/#m2).  However,  in  absolute 
terms, the labeling density in these two organelles were simi- 
lar (4.0 compared with 4.7) (Table II). Because mitochondria 
are larger and more numerous than peroxisomes, the esti- 
mated total contribution of mitochondria to the hepatic im- 
munoreactive AGT protein was ~13 times that of  the peroxi- 
somes in patient 2 (Table II). As in the case of patient 1, the 
main cause appeared to be the increased numbers of mito- 
Danpure  et  al.  Peroxisomal Enzyme Rerouted to Mitochondria  1347 Figure 3. Immunoblot of  a sucrose gradient (patient 1). (a) Fractions 1-17  are from the same sucrose gradient as that in Fig. 1. C, cytoplasmic 
fraction loaded onto gradient (under loaded, but showed both 40- and 43-kD bands); P and M, positions of peroxisomal and mitochondrial 
markers, respectively. (b) Selected fractions from the same gradient showing more clearly the equivalence of the mitochondrial 40-kD 
band and the cytosolic 43-kD band with those in the cytoplasmic (postnuclear supernatant) fraction. 7, 17, and C, fraction 7, fraction 17, 
and cytoplasmic fraction, respectively; 100 agt,  100 ng AGT standard; 25 agt, 25 ng AGT standard. 
chondria labeled  (Table III),  but  in  patient 2,  significant 
numbers of peroxisomes were also labeled (Fig 5, Table III). 
This abnormal intracellular distribution of AGT appears 
to be specific and is not found with other peroxisomal en- 
zymes. For example,  sucrose gradient fractionation of the 
liver from patient 1 (Fig.  1) showed that the distribution of 
D-amino acid oxidase peaked at a density of 'x,1.24 g/cm  3, 
which agrees with that found before for peroxisomes in con- 
trol human livers (Danpure and Jennings, 1988). In addition, 
when  the  intracellular distribution  of catalase  was  inves- 
tigated by protein A-gold immunocytochemistry in the livers 
of patients 1 and 2, it was found to be peroxisomal, the mito- 
chondria being free from label (Fig. 6). 
Discussion 
The intracellular distribution of AGT in mammalian liver is 
species dependent. It is located in the peroxisomes in pri- 
mates and lagomorphs (Noguchi and Takada,  1978b,  1979; 
Takada and Noguchi,  1982b), in the mitochondria in carni- 
vores (Noguchi and  Takada,  1978b;  Okuno  et al.,  1979; 
Takada and Noguchi, 1982b) and in both organeUes in rodents 
(Noguchi et al.,  1978a,  1979; Noguchi and Takada, 1978a; 
Oda et al.,  1982; Takada and Noguchi,  1982b). In human 
liver, its exclusive peroxisomal localization has been demon  - 
strated using both homogenization centrifugation (Noguchi 
and Takada, 1979) and immunocytochemical (Yokota et al., 
1987; Cooper et al., 1988a,b) techniques. To the best of our 
knowledge, this is the first report of mitochondrial AGT in 
the human. 
As the severity of the disease in the two PHI patients was 
considerably worse than expected simply on the basis of  their 
overall residual AGT activity, it would appear that their par- 
ticular form of PHI was due, at least in part, to a mislocaliza- 
tion of their AGT. The implication of this is that, in human 
liver at least, AGT can not perform its metabolic function 
adequately, when located in the mitochondria. This is rea- 
sonable, if the major intracellular site of glyoxylate produc- 
tion in human liver is in the peroxisomes, as might be ex- 
pected from the intracellular localization of D-amino acid 
oxidase (glycine ~  glyoxylate) and L-2-hydroxy  acid oxidase 
(glycolate --" glyoxylate) (De  Duve and  Baudhuin,  1966; 
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Figure 4. Subcellular distribution 
of AGT activity on a Percoll gra- 
diem (patient 1). A, AGT; B, glu- 
tamate dehydrogenase (mitochon- 
dria);  C,  cytochrome  oxidase 
(mitochondria); D, catalase (per- 
oxisomes). Fraction 1, bottom of 
gradient. Units of enzyme activ- 
ity equal percent of total gradient 
activity recovered in each  frac- 
tion. 
Peters and Seymour,  1978).  A  survey of the literature has 
failed to find any other examples of genetic diseases in mam- 
mals caused by trafficking defects leading to the rerouting or 
partial rerouting of an enzyme from one organelle to another 
(see Rosenberg et al.,  1987). 
The failure in the processes involved in the uptake of AGT 
into the peroxisomes would appear to be specific for this en- 
zyme, as the distribution of catalase and D-amino acid oxi- 
dase was unaltered. In addition, a generalized deficiency in 
the uptake of peroxisomal proteins, as might occur in Zell- 
weger's syndrome (Santos et al.,  1988), would be very un- 
likely partly because peroxisomal morphology was relatively 
normal  in  these patients  and partly because they did not 
suffer from any of the wide ranging symptoms characteristic 
of generalized  peroxisomal  deficiency  (Schutgens  et  al., 
1986). 
Presumably the mutational event(s) directly or indirectly 
affect  the signal peptides or organdie receptors. It is not clear 
whether peroxisomal and mitochondrial AGT are coded for 
by the same or different genes. The former is perhaps more 
likely because, in rats, the peroxisomal and mitochondrial 
forms of AGT appear to be identical (Noguchi et al.,  1978b) 
as do the parts of the respective mRNAs coding for the ma- 
ture enzymes (Oda et al.,  1985). In addition, the identical 
rates of evolution of peroxisomal and mitochondrial AGT 
suggest that they did not arise by gene duplication (Takada 
and Noguchi,  1982a; Wilson et al.,  1977). 
The molecular basis  for the dual location of AGT is at 
present unclear. Studies on serine/pyruvate aminotransferase 
(SPT), which is the same gene product as AGT (Noguchi and 
Takada,  1978a; Noguchi et al.,  1978b), have shown that in 
rat liver, two different sized mRNAs for AGT exist (Oda et 
al., 1981, 1985, 1987). The larger, which codes for the mito- 
chondrial SPT, and the mitochondrial SPT protein itself are 
selectively induced by gluconeogenic stimuli such as gluca- 
gon (Oda et al., 1981, 1982), the smaller mRNA and perox- 
isomal SPT activity remain unaltered.  The cDNA for rat 
liver SPT has been sequenced and the putative mitochondrial 
signal sequence identified (Oda et al.,  1987).  Presumably, 
in humans, there has been an evolutionary loss of a  func- 
tional mitochondrial signal or receptor. The molecular na- 
ture of this loss would appear to be constrained by the fact 
that function is restored, albeit partially, by the mutation(s) 
occurring in the two PHI patients presented here. 
Immunoblots  of both  patients'  livers  demonstrated  the 
Table IL  Morphometric  Analysis  of Peroxisomal  and Mitochondrial  Gold Labeling 
Peroxisomes  (P)  Mitochondria  (M) 
Gold  Perox  Total  Gold  Mito  Total  Total  Ratio 
labeling  profile  Perox  perox  labeling  profile  Mito  mito  gold  M/P 
density  area  frequency  gold  density  area  frequency  gold  (P+M)  gold 
Control  1  75.0  0.21  10.1  159,0  0.15  0.27  38.3  1.6  161.0  0.01 
(2.2)  (<0.01)  (0.30)  (<0.01)  (<0.01)  (0.58) 
Control 2  168.0  0.18  19.4  587.0  0.23  0.21  65.6  3.2  590.0  0.005 
(2.9)  (<0.01)  (0.56)  (<0.01)  (<0.01)  (0.53) 
Control 3  29.0  0.18  8.2  43.0  0.25  0.26  48.3  3.1  46.0  0.07 
(1.3)  (<0.01)  (0.41)  (<0.01)  (<0.01)  (0.56) 
Patient 1  0.7  0.14  9.0  0.9  2.2  0.27  25.2  15.0  16.0  17 
(0.02)  (<0.01)  (0.42)  (0.13)  (<0.01)  (0.59) 
Patient 2  4.0  0.18  5.9  4.2  4.7  0.35  32.8  54.0  58.0  13 
(0.04)  (<0.01)  (0.35)  (0.19)  (<0.01)  (0.66) 
Control  1 is a patient suffering from Gilbert's disease. Control 2 is a schizophrenic patient suffering from chlorpromazine toxicity who showed evidence of perox- 
isomal and mitochondrial proliferation  and high AGT activity, Control  3 is an obligate PHI beterozygote with 30% of normal AGT activity.  Patient  I is a PHI 
patient with 9% AGT activity.  Patient 2 is a PHI patient with 27% of normal AGT activity. The values are means with SEM in brackets.  Gold labeling density 
(L), gold particles per micrometers squared. Profile area (A), organdie area in micrometers squared. Organelle frequency (N), number of mitochondria or peroxi- 
somcs/100 ttm  2 of cytoplasm.  For the estimation of mean areas and labeling densities in the peroxisomes,  n  =  123-203 organdies; for the mitochondria,  n  = 
300-772.  For the estimations of organelle  frequency,  1,268-1,902  ~tm  2 of tissue were analyzed.  Total mitochondrial or peroxisomal gold (T) is an estimate of 
total organellar  labeling in 100/zm 2 of cytoplasm (T =  L  × A  ×  N). The background (cytoplasmic) labeling varied between 0.07  and 0.19  gold particles/#m 2 
(total cytoplasmic area measured varied between 560 and  1,850/xm:  for each patient).  Control  incubations,  using preimmune  serum gave background  labeling 
of 0.12  gold particles/pm 2 (SEM  =  0.02). 
Danpure et al. Peroxisomal Enzyme Rerouted to Mitochondria  1349 Figure 5. Protein A-gold immunocytochemistry of AGT in liver biopsies, a, control 2; b, control 3 (obligate PHI heterozygote); c, patient 1; 
d,  patient 2.  M, mitochondria; P, peroxisomes. Bars, 0.5  #m. 
presence  of an  immunoreactive  protein  with  a  molecular 
mass ,02-3 kD larger than the main AGT band.  This corre- 
sponds very closely with the size of the precursor mitochon- 
drial AGT protein in the rat, as predicted by the cDNA se- 
quence  (Oda  et  al.,  1987).  However  its  significance  is 
unclear as it can also be detected in some individuals  (nor- 
mals and  PHI  patients)  who do  not possess  mitochondrial 
AGT (unpublished  observations).  When present,  this puta- 
tive precursor AGT appears to be confined to the cytosolic 
compartment. 
The Journal of Cell Biology, Volume  108, 1989  1350 Table IlL Proportion of  Peroxisomes and 
Mitochondria Labeled 
Percent of each organelle  labeled 
Peroxisomes  Mitochondria  Cytoplasm 
Control  1  100 (75)  4  (4.2)  (0.07) 
Control 2  100  (168)  5  (4.6)  (0.11) 
Control  3  100 (29)  4  (5.8)  (0.07) 
Patient  1  11  (6.3)  42  (5.3)  (0.19) 
Patient 2  47  (8.4)  71  (6.6)  (0.11) 
Values obtained from the morphometric  analysis performed for Table II. Values 
in brackets  equal the mean gold labeling density of the positively  labeled or- 
ganelle  profiles  only (i.e., discounting  unlabeled  profiles).  The cytoplasmic 
values are equivalent  m the background  from Table  II. 
The lower amounts of AGT enzyme activity and protein 
in patients 1 and 2 is not surprising as they would be expected 
to be heterozygous for the mitochondrial AGT allele. In addi- 
tion, the evolutionary inactivation of the mitochondrial route 
for AGT translocation in the human would have enabled ran- 
dom mutational events to occur, due to the relaxation of se- 
lection pressure.  Reuse of this vestigial pathway results in 
low efficiency translocation of AGT, possibly due to altera- 
tions in posttranslational processing or receptor/signal func- 
tioning. 
The molecular basis of mitochondrial signaling has re- 
ceived much attention but hardly anything is known with re- 
spect to peroxisomal  signaling. In general,  mitochondrial 
signal sequences are NH2-terminal  and cleaved (Schatz and 
Butow,  1983;  Hay et  al.,  1984;  Schatz,  1987),  whereas 
peroxisomal signals may be COOH-terminal (Keller et al., 
1987;  Gould et al.,  1987; Small and Lazarow,  1987)  and 
probably not cleaved (Goldman and Blobel, 1978). The fas- 
cinating possibility exists that the AGT gene codes for, and 
the nascent gene product possess, both peroxisomal and mi- 
tochondrial signals.  Therefore the combination of the un- 
usual properties of AGT and PH1 may provide an extremely 
useful model system in which to study peroxisomal/mito- 
chondrial targetting and the hierarchy involved (Colman and 
Richardson,  1986). 
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J. Storey (Electron Microscopy Unit, King's College, London) for the use 
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